Fabrication of Biomimetic Hybrid Liposomes via Microfluidic Technology: Homotypic Targeting and Antitumor Efficacy Studies in Glioma Cells.

Autor:	Arduino I; Department of Pharmacy-Pharmaceutical Sciences, University of Bari, Bari, 70125, Italy., Di Fonte R; IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, 70124, Italy., Sommonte F; IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, 70124, Italy., Lopedota AA; Department of Pharmacy-Pharmaceutical Sciences, University of Bari, Bari, 70125, Italy., Porcelli L; IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, 70124, Italy., Li J; Department of Biomaterials and Biomedical Technology, University Medical Center Groningen (UMCG), The Personalized Medicine Research Institute (PRECISION), University of Groningen, Groningen, AV, 9713, Netherlands., Serrati S; IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, 70124, Italy., Bártolo R; Department of Biomaterials and Biomedical Technology, University Medical Center Groningen (UMCG), The Personalized Medicine Research Institute (PRECISION), University of Groningen, Groningen, AV, 9713, Netherlands., Santos HA; Department of Biomaterials and Biomedical Technology, University Medical Center Groningen (UMCG), The Personalized Medicine Research Institute (PRECISION), University of Groningen, Groningen, AV, 9713, Netherlands., Iacobazzi RM; Department of Pharmacy-Pharmaceutical Sciences, University of Bari, Bari, 70125, Italy., Azzariti A; IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, 70124, Italy., Denora N; Department of Pharmacy-Pharmaceutical Sciences, University of Bari, Bari, 70125, Italy.
Jazyk:	angličtina
Zdroj:	International journal of nanomedicine [Int J Nanomedicine] 2024 Dec 08; Vol. 19, pp. 13217-13233. Date of Electronic Publication: 2024 Dec 08 (Print Publication: 2024).
DOI:	10.2147/IJN.S489872
Abstrakt:	Introduction: The treatment of glioblastoma is hindered by the blood-brain barrier (BBB) and rapid drug clearance by the immune system. To address these challenges, we propose a novel drug delivery system using liposomes modified with cell membrane fragments. These modified liposomes can evade the immune system, cross the BBB, and accumulate in tumor tissue through homotypic targeting, thereby delivering drugs like paclitaxel and carboplatin more effectively. Methods: In this work, the hybrid liposomes were synthesized using microfluidics and integrating 3D printing to produce the microfluidic devices. In vitro, we explored the homotypic targeting capability, BBB passing ability, and therapeutic efficacy of paclitaxel and carboplatin. Results: The production of hybrid liposomes by microfluidics has been key to creating high-quality biomimetic nanoparticles, and the integration of 3D printing has simplified the production of microfluidic devices, making the process more efficient and economical. In vitro experiments have shown that these drug-loaded biomimetic hybrid liposomes are able to reach the homotypic target, cross the BBB, and maintain the efficacy of paclitaxel and carboplatin. Conclusions: The development of biomimetic hybrid liposomes represents a promising approach for the treatment of glioblastoma. By combining the advantages of liposomal drug delivery with the stealth properties and targeting capabilities of cell membrane fragments, these nanoparticles can potentially overcome the challenges associated with traditional therapies. Competing Interests: The authors of this paper declare no competing financial or other interests that could affect the work they describe here. (© 2024 Arduino et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu